Brief: EMA Starts Review Of Ixchiq Following Reports Of Serious Adverse Events In Elderly People
07/05/2025 14:43
May 7 (Reuters) - EMA: EMA STARTS REVIEW OF IXCHIQ (LIVE ATTENUATED CHIKUNGUNYA VACCINE) EMA: STARTED REVIEW OF IXCHIQ (A LIVE ATTENUATED CHIKUNGUNYA VACCINE) FOLLOWING REPORTS OF SERIOUS ADVERSE EVENTS IN ELDERLY PEOPLE EMA: IXCHIQ VACCINE MUST NOT BE USED IN PEOPLE 65 YEARS AND ABOVE WHILE REVIEW IS UNDERWAY - WEBSITE EMA: MANY PEOPLE AFFECTED ALSO HAD OTHER ILLNESSES, EXACT CAUSE OF ADVERSE EVENTS & RELATIONSHIP WITH VACCINE NOT YET DETERMINED EMA: IXCHIQ VACCINATION CAN CONTINUE IN PEOPLE UNDER 65 YEARS OF AGE, IN ACCORDANCE WITH OFFICIAL RECOMMENDATIONS EMA: SO FAR 17 SERIOUS ADVERSE EVENTS, INCLUDING 2 CASES OF DEATH, REPORTED WORLDWIDE IN PEOPLE AGED BETWEEN 62 AND 89 YEARS WHO RECEIVED IXCHIQ Further company coverage: VLS.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency